SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (985)11/30/1997 3:55:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear Henry:

AMLN did say in their first clinical III for type II that the drug group had used decreased amount of insulin while the control group had increased insulin use. However, that was because they did not control the amount of insulin taking by all patients in the trial. Thus, the therapeutic function of pramlintide for blood sugar lowering was replaced by the decreased use of insulin. For the on-going trials, making sure all patients use steady amount of insulin is THE priority. I for one sure hope they don't show pramlintide can reduce insulin usage by patients in the on-going trials. However, patients can use it for that purpose once the drug gets its approval. That is NOT an off-label use. I believe diabetic patients are the best doctors themself, they know what to do for their body better than any physican they can have.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News